Human Immunology's (HI-Bio) felzartamab has completed mid-stage studies for a type of kidney disease called primary membranous nephropathy, and in patients with a disease where the immune system makes antibodies that damage their transplanted organ. The San Francisco-based company is also testing the therapy in patients with another chronic kidney disease known as IgA nephropathy. Since Christopher Viehbacher took the helm in late 2022, Biogen has acquired rare disease drugmaker Reata for $6.5 billion, abandoned its controversial Alzheimer's disease drug Aduhelm and cut jobs.
Biogen to Pay Up to $1 8 Billion for Immune Drug Developer bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
WESTON (dpa-AFX) - Biogen Inc. (BIIB) and privately-held biotechnology company Human Immunology Biosciences or HI-Bio, announced Wednesday the companies have entered into a definitive agreement
Biogen announces an agreement to acquire Human Immunology Biosciences , an unlisted clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases.